Biological

Phase 1Biologic

NNational Environment Agency, Singapore

Biological is one of 21 biologic programs targeting SCLC, Extensive Stage. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SCLC, Extensive StageRecruiting

Refractory/relapse NeuroblastomaRecruiting

SarcomaRecruiting

DengueRecruiting

SCLC, Extensive StagePhase 1

Recruiting

Refractory/relapse NeuroblastomaPhase 1

Recruiting

SarcomaPhase 1

Recruiting

DenguePreclinical

Recruiting

Competition

Competitive Landscape

18 competitors in Sarcoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Opdivo

Bristol-Myers Squibb

Phase 2

2 3

Tecentriq

Roche

Phase 2

1 4

IC-Green

PProvepharm SAS

Phase 2

1 5

Amtagvi

IIovance Biotherapeutics, Inc.

Phase 2

1 6

Talimogene Laherparepvec

Amgen

Phase 2

3 7

NKTR-214

Bristol-Myers Squibb

Phase 2

1 8

Rapamune

PPrism Pharmaceuticals

Preclinical

1 9

Biological

NNational Environment Agency, Singapore

Phase 1

1 10

NEULASTA

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

SCLC, Extensive Stage

NCT07366658

Q3 2027

Phase 1Recruiting

Refractory/relapse Neuroblastoma

NCT05608148

Q1 2028

N/ARecruiting

Dengue

NCT06894901

Q2 2029

Phase 3Recruiting

Intracerebral Hemorrhage

NCT07227246

Clinical

Trials by Indication[1]

Dengue2 trials

Impact of Project Wolbachia - Singapore on Dengue Incidence

Completed·NNational Environment Agency, Singapore·N/A·NCT05505682·724,428 enrolled

Impact of IIT-SIT on Dengue Clusters

Recruiting·NNational Environment Agency, Singapore·N/A·NCT06894901·900 enrolled

Crohn's Disease1 trial

COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk)

Completed·UUniversity Hospital, Lille··NCT02839317·214 enrolled

Treatment1 trial

Collagenase in the Treatment of Cellulite

Unknown status·SStony Brook University·Phase 2·NCT00261144·20 enrolled

Type 1 Diabetes Mellitus1 trial

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

Unknown status·DDiaVacs, Inc.·Phase 1/2·NCT01947569·90 enrolled

COVID-191 trial

Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease

Completed·HHospital Central Militar·Phase 2·NCT04542967·150 enrolled

6 more indications

NSCLC1 trial

Phase I / II Clinical Trial of GAIA-102 for Advanced and Relapse NSCLC

Terminated·GGAIA BioMedicine Inc.·Preclinical·NCT05207371·22 enrolled

Intracerebral Hemorrhage1 trial

Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial - Part 2

Recruiting·JJoseph Broderick, MD·Phase 3·NCT07227246·350 enrolled

House Dust Mite Allergy1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite

Completed·HHAL Allergy·Phase 3·NCT06920771·691 enrolled

Sarcoma1 trial

Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma

Recruiting·UUniversity College, London·Phase 1·NCT07751380·12 enrolled

Refractory/Relapse Neuroblastoma1 trial

Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors

Recruiting·KKyushu University·Phase 1·NCT05608148·61 enrolled

SCLC, Extensive Stage1 trial

A Study to Explore the Safety, Tolerability, and Preliminary Efficacy of NEUK203-13 Injection in Patients With Neuroendocrine Tumors Who Have Failed Systemic Therapy

Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 1·NCT07366658·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for Biological. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biological compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biological. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Environment Agency, Singapore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: NNational Environment Agency, Singapore

Biological

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q1 2028

Q2 2029

Trials by Indication[1]

Dengue2 trials

Crohn's Disease1 trial

Treatment1 trial

Type 1 Diabetes Mellitus1 trial

COVID-191 trial

NSCLC1 trial

Intracerebral Hemorrhage1 trial

House Dust Mite Allergy1 trial

Sarcoma1 trial

Refractory/Relapse Neuroblastoma1 trial

SCLC, Extensive Stage1 trial

References

Drug Info

Quick Facts

Related News